<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486824</url>
  </required_header>
  <id_info>
    <org_study_id>97873</org_study_id>
    <nct_id>NCT00486824</nct_id>
  </id_info>
  <brief_title>Indomethacin Versus Nifedipine for Preterm Labor Tocolysis</brief_title>
  <official_title>Indocin Versus Nifedipine for Preterm Labor Tocolysis - A Randomized Double-Blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indomethacin and Nifedipine are commonly used medications for treatment of pre term labor.
      This study will compare the efficacy and adverse outcomes of oral nifedipine versus oral
      indomethacin for preterm labor tocolysis in an effort to identify which drug is most
      effective.

      Patients diagnosed with preterm labor who grant consent will be randomized by the pharmacy to
      receive oral nifedipine or oral indomethacin. Both the patient and primary medical provider
      will be blinded to the identity of the study drug. An abdominal ultrasound will be performed
      in the labor and delivery unit prior to the administration of the tocolytic in order to
      assess fetal position and fluid level, and to document fetal cardiac activity and movement,
      and will be repeated at 48 hours post-randomization. Following randomization, the patient
      will be given either 50 mg oral indomethacin with two pills of placebo, or 3 pills each
      containing 10 mg oral nifedipine for a total of 30 mg. The patients will then receive either
      25 mg of oral indomethacin every 6 hours for 48 hours, or 20 mg of oral nifedipine every 6
      hours for 48 hours. Tocolysis beyond 48 hours will not be used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presenting between 24-34 weeks gestation diagnosed with preterm labor who grant
      consent will be randomized by the pharmacy to receive oral nifedipine or oral indomethacin.
      Both the patient and primary medical provider will be blinded to the identity of the study
      drug. An abdominal ultrasound will be performed in the labor and delivery unit prior to the
      administration of the tocolytic in order to assess fetal position and fluid level, and to
      document fetal cardiac activity and movement, and will be repeated at 48 hours
      post-randomization. Following randomization, the patient will be given either 50 mg oral
      indomethacin with two pills of placebo, or 3 pills each containing 10 mg oral nifedipine for
      a total of 30 mg. The patients will then receive either 25 mg of oral indomethacin every 6
      hours for 48 hours, or 20 mg of oral nifedipine every 6 hours for 48 hours. Tocolysis beyond
      48 hours will not be used. Antibiotics and steroids for fetal lung maturity will be
      administered as per standard of care for preterm labor. Maternal side effects and delivery
      outcomes will be assessed from questionnaires administered by the study team following
      treatment, and/or from review of the patient's medical records.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2007</start_date>
  <completion_date type="Actual">December 8, 2012</completion_date>
  <primary_completion_date type="Actual">December 8, 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Patients With Recurrent Preterm Labor Within Two Weeks of Randomization</measure>
    <time_frame>Two weeks after enrolled and randomized, up to 37 weeks of pregnancy</time_frame>
    <description>Preterm labor was defined as documented cervical change and regular uterine contractions at least every 5 minutes, or at least 2 cm cervical dilation and 80% cervical effacement. Preterm labor is defined as uterine contractions occurring up to 37 weeks of pregnancy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal Birthweight</measure>
    <time_frame>Until discharge of mother and neonate from delivery hospital, up to 30 days after delivery</time_frame>
    <description>Birthweight is presented in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Delivery</measure>
    <time_frame>Up to 42 weeks of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days From First Medication Initiation to Delivery as a Measure of Delay in Delivery</measure>
    <time_frame>Up to 42 weeks of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Neonatal Morbidity</measure>
    <time_frame>Up to 42 weeks of pregnancy</time_frame>
    <description>Neonatal morbidity included admission to neonatal intensive care unit, respiratory distress or sepsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Side-effect Due to the Medication</measure>
    <time_frame>Up to 42 weeks of pregnancy</time_frame>
    <description>Monitored side-effects for this outcome included abdominal pain, blood pressure change, GI-symptoms and skin rash.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Uterine Quiescence</measure>
    <time_frame>Up to 42 weeks of pregnancy</time_frame>
    <description>Uterine quiescence was defined as six or fewer uterine contractions per hour. Outcome was described as days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Obstetric Labor, Premature</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
    <arm_group_label>Nifedipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton and twin gestations

          -  Intact amniotic membranes

          -  No contra-indications to tocolysis

          -  24-34 weeks gestation by last menstrual period and/or ultrasound

          -  Documented cervical change, and regular painful uterine contractions at least every 5
             minutes, or at least 2 cm cervical dilation and 80% effacement

        Exclusion Criteria:

          -  Ruptured amniotic membranes

          -  Signs/symptoms of chorioamnionitis (maternal temperature greater than 100.4 F/38.0 C,
             fetal tachycardia, uterine tenderness)

          -  Non-reassuring fetal heart rate tracings

          -  Contra-indications to indomethacin or nifedipine

          -  Contra-indications to tocolysis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Judith Lyell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2007</study_first_posted>
  <results_first_submitted>August 31, 2018</results_first_submitted>
  <results_first_submitted_qc>August 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2018</results_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Deirdre Judith Lyell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 29 patients were initially consented and enrolled. Patients were enrolled through December 2012 but protocol remained open until 2018. Due to patient privacy regulations, the data were accessible for only 10 patients.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Indomethacin</title>
          <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
        </group>
        <group group_id="P2">
          <title>Nifedipine</title>
          <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data were accessible for limited participants due to patient privacy regulations.</population>
      <group_list>
        <group group_id="B1">
          <title>Indomethacin</title>
          <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
        </group>
        <group group_id="B2">
          <title>Nifedipine</title>
          <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" lower_limit="20.0" upper_limit="37.0"/>
                    <measurement group_id="B2" value="30" lower_limit="19.0" upper_limit="37.0"/>
                    <measurement group_id="B3" value="26.5" lower_limit="19.0" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Patients With Recurrent Preterm Labor Within Two Weeks of Randomization</title>
        <description>Preterm labor was defined as documented cervical change and regular uterine contractions at least every 5 minutes, or at least 2 cm cervical dilation and 80% cervical effacement. Preterm labor is defined as uterine contractions occurring up to 37 weeks of pregnancy.</description>
        <time_frame>Two weeks after enrolled and randomized, up to 37 weeks of pregnancy</time_frame>
        <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Patients With Recurrent Preterm Labor Within Two Weeks of Randomization</title>
          <description>Preterm labor was defined as documented cervical change and regular uterine contractions at least every 5 minutes, or at least 2 cm cervical dilation and 80% cervical effacement. Preterm labor is defined as uterine contractions occurring up to 37 weeks of pregnancy.</description>
          <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Birthweight</title>
        <description>Birthweight is presented in grams</description>
        <time_frame>Until discharge of mother and neonate from delivery hospital, up to 30 days after delivery</time_frame>
        <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Birthweight</title>
          <description>Birthweight is presented in grams</description>
          <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2830" lower_limit="2750" upper_limit="2880"/>
                    <measurement group_id="O2" value="2240" lower_limit="2000" upper_limit="2740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Delivery</title>
        <time_frame>Up to 42 weeks of pregnancy</time_frame>
        <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at Delivery</title>
          <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" lower_limit="35.0" upper_limit="37.4"/>
                    <measurement group_id="O2" value="34.0" lower_limit="33.4" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days From First Medication Initiation to Delivery as a Measure of Delay in Delivery</title>
        <time_frame>Up to 42 weeks of pregnancy</time_frame>
        <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
          </group>
        </group_list>
        <measure>
          <title>Days From First Medication Initiation to Delivery as a Measure of Delay in Delivery</title>
          <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="22.0" upper_limit="77.0"/>
                    <measurement group_id="O2" value="36.0" lower_limit="28.0" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Neonatal Morbidity</title>
        <description>Neonatal morbidity included admission to neonatal intensive care unit, respiratory distress or sepsis.</description>
        <time_frame>Up to 42 weeks of pregnancy</time_frame>
        <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Neonatal Morbidity</title>
          <description>Neonatal morbidity included admission to neonatal intensive care unit, respiratory distress or sepsis.</description>
          <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Side-effect Due to the Medication</title>
        <description>Monitored side-effects for this outcome included abdominal pain, blood pressure change, GI-symptoms and skin rash.</description>
        <time_frame>Up to 42 weeks of pregnancy</time_frame>
        <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Side-effect Due to the Medication</title>
          <description>Monitored side-effects for this outcome included abdominal pain, blood pressure change, GI-symptoms and skin rash.</description>
          <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Uterine Quiescence</title>
        <description>Uterine quiescence was defined as six or fewer uterine contractions per hour. Outcome was described as days.</description>
        <time_frame>Up to 42 weeks of pregnancy</time_frame>
        <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Uterine Quiescence</title>
          <description>Uterine quiescence was defined as six or fewer uterine contractions per hour. Outcome was described as days.</description>
          <population>Participants with accessible data are included in the analysis. Not all data were accessible due to patient data privacy regulations.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.75" upper_limit="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to maternal and neonatal discharge from the delivery hospital, up to 30 days after the delivery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Indomethacin</title>
          <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Indomethacin: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
        </group>
        <group group_id="E2">
          <title>Nifedipine</title>
          <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Nifedipine: Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size for the analysis was not reached.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Deirdre Lyell</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507255720</phone>
      <email>dlyell@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

